首页 > 最新文献

Melanoma Research最新文献

英文 中文
Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study. 肠道微生物群与皮肤黑色素瘤之间的遗传因果关系:双样本孟德尔随机研究。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-11 DOI: 10.1097/CMR.0000000000000960
Peizhou Wang, Tun Liu, Qingguo Zhang, Pan Luo

Currently, numerous studies suggest a potential association between the gut microbiota and the progression of melanoma. Hence, our objective was to examine the genetic impact of the gut microbiota on melanoma through the utilization of the Mendelian randomization (MR) approach. This research employed Bacteroides, Streptococcus, Proteobacteria, and Lachnospiraceae as exposure variables and cutaneous melanoma (CM) as the outcome in a two-sample MR analysis. In this MR research, the primary analytical approach was the random-effects inverse-variance weighting (IVW) model. Complementary methods included weighted median, MR Egger, and basic and weighted models. We assessed both heterogeneity and horizontal pleiotropy in our study, scrutinizing whether the analysis results were affected by any individual SNP. The random-effects IVW outcomes indicated that Streptococcus, Bacteroides, Lachnospiraceae and Proteobacteria had no causal relationship with CM, with odds ratios of 1.001 [95% confidence interval (CI) = 0.998-1.004, P  = 0.444], 0.999 (95% CI = 0.996-1.002, P  = 0.692), 1.001 (95% CI = 0.998-1.003, P  = 0.306), and 0.999 (95% CI = 0.997-1.002, P  = 0.998), respectively. No analyses exhibited heterogeneity, horizontal pleiotropy, or deviations. Our research determined that Bacteroides, Streptococcus, Proteobacteria, and Lachnospiraceae do not induce CM at the genetic level. However, we cannot dismiss the possibility that these four gut microbiotas might influence CM through other mechanisms.

目前,许多研究表明,肠道微生物群与黑色素瘤的进展之间存在潜在联系。因此,我们的目标是通过孟德尔随机化(MR)方法,研究肠道微生物群对黑色素瘤的遗传影响。本研究采用乳酸菌、链球菌、变形菌和漆螺菌作为暴露变量,以皮肤黑色素瘤(CM)作为结果,进行双样本 MR 分析。在这项磁共振研究中,主要分析方法是随机效应逆方差加权(IVW)模型。补充方法包括加权中位数、MR Egger、基本模型和加权模型。我们在研究中评估了异质性和水平多向性,仔细检查分析结果是否受到任何单个 SNP 的影响。随机效应 IVW 结果表明,链球菌属、乳杆菌属、拉克氏螺旋体属和变形菌属与 CM 没有因果关系,其几率比为 1.001 [95% 置信区间 (CI) = 0.998-1.004,P = 0.444]、0.999(95% CI = 0.996-1.002,P = 0.692)、1.001(95% CI = 0.998-1.003,P = 0.306)和 0.999(95% CI = 0.997-1.002,P = 0.998)。没有分析显示异质性、水平多效性或偏差。我们的研究确定,乳酸杆菌、链球菌、变形菌和漆树菌在基因水平上不会诱导中耳炎。但是,我们不能排除这四种肠道微生物通过其他机制影响中风的可能性。
{"title":"Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study.","authors":"Peizhou Wang, Tun Liu, Qingguo Zhang, Pan Luo","doi":"10.1097/CMR.0000000000000960","DOIUrl":"10.1097/CMR.0000000000000960","url":null,"abstract":"<p><p>Currently, numerous studies suggest a potential association between the gut microbiota and the progression of melanoma. Hence, our objective was to examine the genetic impact of the gut microbiota on melanoma through the utilization of the Mendelian randomization (MR) approach. This research employed Bacteroides, Streptococcus, Proteobacteria, and Lachnospiraceae as exposure variables and cutaneous melanoma (CM) as the outcome in a two-sample MR analysis. In this MR research, the primary analytical approach was the random-effects inverse-variance weighting (IVW) model. Complementary methods included weighted median, MR Egger, and basic and weighted models. We assessed both heterogeneity and horizontal pleiotropy in our study, scrutinizing whether the analysis results were affected by any individual SNP. The random-effects IVW outcomes indicated that Streptococcus, Bacteroides, Lachnospiraceae and Proteobacteria had no causal relationship with CM, with odds ratios of 1.001 [95% confidence interval (CI) = 0.998-1.004, P  = 0.444], 0.999 (95% CI = 0.996-1.002, P  = 0.692), 1.001 (95% CI = 0.998-1.003, P  = 0.306), and 0.999 (95% CI = 0.997-1.002, P  = 0.998), respectively. No analyses exhibited heterogeneity, horizontal pleiotropy, or deviations. Our research determined that Bacteroides, Streptococcus, Proteobacteria, and Lachnospiraceae do not induce CM at the genetic level. However, we cannot dismiss the possibility that these four gut microbiotas might influence CM through other mechanisms.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"225-233"},"PeriodicalIF":2.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140101999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity. 吲哚菁绿用于监测肢体离体灌注治疗复发性黑色素瘤期间全身药物泄漏的可行性和有效性。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-06-01 Epub Date: 2024-03-15 DOI: 10.1097/CMR.0000000000000967
Sri Siddharth Nekkanti, Syed Nusrath, Rajesh Jarang, Basanth Kumar Rayani, Yerramshetty Vamshi Krishna, Kalidindi Venkata Vijaya Narsimha Raju

Melanoma is known for its high metastatic potential and aggressive growth. Recurrence is common post-surgery, sometimes leading to unresectable disease. Locally recurrent unresectable melanoma of extremity has been treated with high-dose anticancer chemotherapy via isolated limb perfusion (ILP) to improve local efficacy of drug and salvage limbs. Standard ILP monitoring uses radiolabeled dyes, requiring specialized personnel and involving radiation exposure. In this case, we used indocyanine green (ICG) to track systemic drug leakage during ILP. A 47-year-old gentleman with recurrent malignant melanoma of the left foot, operated twice earlier and treated with adjuvant pembrolizumab, presented with multiple in-transit metastases in the limb. ILP was planned, with 5 mg ICG administered in the perfusion solution along with high-dose melphalan. Stryker's SPI PHI handheld device was employed to visualize ICG during ILP. Absence of fluorescence beyond the involved extremity, such as fingers, ears, and the abdominal wall, indicated no systemic drug dispersion. For control, technetium radiocolloid dye was co-administered, monitored by a precordial gamma probe, confirming no systemic leakage, and validating effectiveness of ICG in leakage monitoring. ICG proves to be a safe, reliable, cost-effective, radiation-free approach for precise systemic drug leakage monitoring during ILP for recurrent melanoma of extremity.

众所周知,黑色素瘤具有高度转移性和侵袭性生长。术后复发很常见,有时会导致无法切除的疾病。局部复发且无法切除的肢体黑色素瘤可通过离体肢体灌注(ILP)进行大剂量抗癌化疗,以提高药物的局部疗效并挽救肢体。标准的 ILP 监测使用放射性标记染料,需要专业人员并涉及辐射暴露。在本病例中,我们使用吲哚菁绿(ICG)来跟踪 ILP 期间的全身药物渗漏情况。一名 47 岁的男性左脚复发性恶性黑色素瘤患者曾接受过两次手术,并接受过 pembrolizumab 的辅助治疗。计划进行 ILP,在灌注液中加入 5 毫克 ICG 和大剂量美法仑。史赛克的 SPI PHI 手持设备用于在 ILP 期间观察 ICG。受累肢体(如手指、耳朵和腹壁)以外没有荧光,表明药物没有扩散到全身。在对照组中,同时使用了锝放射性胶体染料,并通过心前区伽马探头进行监测,结果证实没有全身性渗漏,同时也验证了 ICG 在渗漏监测方面的有效性。事实证明,ICG 是一种安全、可靠、经济、无辐射的方法,可在治疗四肢复发性黑色素瘤的 ILP 过程中精确监测全身药物渗漏。
{"title":"Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.","authors":"Sri Siddharth Nekkanti, Syed Nusrath, Rajesh Jarang, Basanth Kumar Rayani, Yerramshetty Vamshi Krishna, Kalidindi Venkata Vijaya Narsimha Raju","doi":"10.1097/CMR.0000000000000967","DOIUrl":"10.1097/CMR.0000000000000967","url":null,"abstract":"<p><p>Melanoma is known for its high metastatic potential and aggressive growth. Recurrence is common post-surgery, sometimes leading to unresectable disease. Locally recurrent unresectable melanoma of extremity has been treated with high-dose anticancer chemotherapy via isolated limb perfusion (ILP) to improve local efficacy of drug and salvage limbs. Standard ILP monitoring uses radiolabeled dyes, requiring specialized personnel and involving radiation exposure. In this case, we used indocyanine green (ICG) to track systemic drug leakage during ILP. A 47-year-old gentleman with recurrent malignant melanoma of the left foot, operated twice earlier and treated with adjuvant pembrolizumab, presented with multiple in-transit metastases in the limb. ILP was planned, with 5 mg ICG administered in the perfusion solution along with high-dose melphalan. Stryker's SPI PHI handheld device was employed to visualize ICG during ILP. Absence of fluorescence beyond the involved extremity, such as fingers, ears, and the abdominal wall, indicated no systemic drug dispersion. For control, technetium radiocolloid dye was co-administered, monitored by a precordial gamma probe, confirming no systemic leakage, and validating effectiveness of ICG in leakage monitoring. ICG proves to be a safe, reliable, cost-effective, radiation-free approach for precise systemic drug leakage monitoring during ILP for recurrent melanoma of extremity.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"276-279"},"PeriodicalIF":2.2,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature. 治疗类固醇难治性免疫相关肝毒性的托珠单抗:病例系列和文献综述。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-29 DOI: 10.1097/cmr.0000000000000969
Ahmet Anil Ozluk, Damla Gunenc, Saadet Sim Yildirim, Burcak Karaca
With the widespread use of immune checkpoint inhibitors, management of immune-related adverse effects specific to these treatments became an important research era in patient management. Among these, immune-related hepatotoxicity (IRH) is an adverse event that can be fatal. While the first-line treatment of IRH is well established, there is still no consensus regarding the management approach for steroid-refractory, severe IRH. Here, we report four patients with metastatic melanoma who developed IRH during antiprogrammed cell death protein-1 plus anticytotoxic T-lymphocyte-associated protein-4 combination therapy and review of the literature. All of our patients were steroid-refractory and were successfully treated with tocilizumab. Given the rapid improvement in liver enzymes and patient's clinical status with tocilizumab, this treatment should be prioritized in steroid-refractory IRH.
随着免疫检查点抑制剂的广泛应用,如何处理这些治疗方法所特有的免疫相关不良反应成为患者管理研究的一个重要课题。其中,免疫相关肝毒性(IRH)是一种可能致命的不良反应。虽然IRH的一线治疗方法已经确立,但对于类固醇难治性重度IRH的治疗方法仍未达成共识。在此,我们报告了四例在抗程序性细胞死亡蛋白-1和抗细胞毒性T淋巴细胞相关蛋白-4联合治疗期间出现IRH的转移性黑色素瘤患者,并回顾了相关文献。我们的所有患者都是类固醇难治性患者,并成功接受了托珠单抗治疗。鉴于托西珠单抗能迅速改善肝酶和患者的临床状态,因此类固醇难治性IRH患者应优先考虑这种疗法。
{"title":"Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature.","authors":"Ahmet Anil Ozluk, Damla Gunenc, Saadet Sim Yildirim, Burcak Karaca","doi":"10.1097/cmr.0000000000000969","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000969","url":null,"abstract":"With the widespread use of immune checkpoint inhibitors, management of immune-related adverse effects specific to these treatments became an important research era in patient management. Among these, immune-related hepatotoxicity (IRH) is an adverse event that can be fatal. While the first-line treatment of IRH is well established, there is still no consensus regarding the management approach for steroid-refractory, severe IRH. Here, we report four patients with metastatic melanoma who developed IRH during antiprogrammed cell death protein-1 plus anticytotoxic T-lymphocyte-associated protein-4 combination therapy and review of the literature. All of our patients were steroid-refractory and were successfully treated with tocilizumab. Given the rapid improvement in liver enzymes and patient's clinical status with tocilizumab, this treatment should be prioritized in steroid-refractory IRH.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"74 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140826709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition. 一名接受 PD-1 和 LAG-3 抑制剂治疗的转移性黑色素瘤患者出现假性进展。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-18 DOI: 10.1097/cmr.0000000000000974
Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar
Pseudoprogression encapsulates a process of temporary radiographic growth followed by subsequent regression of metastatic melanoma lesions in response to immune checkpoint blockade (ICB), such as the combination of anti-programmed cell death protein 1 (PD-1) and anticytotoxic T-lymphocyte-associated antigen 4 therapy. This occurs in approximately 5-10% of ICB-treated patients, but has not yet been described in the context of novel combination therapies. Here, we report a case of an 89-year-old patient with metastatic melanoma to the liver, lung and lymph nodes, who underwent treatment with Opdualag (combining anti-PD-1 nivolumab and anti-lymphocyte-activation gene 3 relatlimab ICBs), and developed pseudoprogression after two cycles of therapy. The patient experienced a radiographic increase in liver metastatic lesion size, but was found to have a subsequent reduction in these lesions. The patient has been on therapy for 18 months without evidence of disease progression and continues to be clinically well-appearing.
假性进展是指转移性黑色素瘤病灶在接受免疫检查点阻断(ICB)治疗(如抗程序性细胞死亡蛋白1(PD-1)和抗细胞毒性T淋巴细胞相关抗原4的联合治疗)后,出现暂时的放射学生长,随后消退的过程。约有 5-10% 接受过 ICB 治疗的患者会出现这种情况,但在新型联合疗法的背景下还未出现过这种情况。在此,我们报告了一例 89 岁的肝脏、肺部和淋巴结转移性黑色素瘤患者,该患者接受了 Opdualag(结合抗 PD-1 nivolumab 和抗淋巴细胞活化基因 3 relatlimab 的 ICB)治疗,并在两个周期治疗后出现假性进展。该患者的肝转移病灶在影像学上有所增大,但随后发现这些病灶有所缩小。患者已经接受了 18 个月的治疗,没有出现疾病进展的迹象,临床表现仍然良好。
{"title":"Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.","authors":"Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar","doi":"10.1097/cmr.0000000000000974","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000974","url":null,"abstract":"Pseudoprogression encapsulates a process of temporary radiographic growth followed by subsequent regression of metastatic melanoma lesions in response to immune checkpoint blockade (ICB), such as the combination of anti-programmed cell death protein 1 (PD-1) and anticytotoxic T-lymphocyte-associated antigen 4 therapy. This occurs in approximately 5-10% of ICB-treated patients, but has not yet been described in the context of novel combination therapies. Here, we report a case of an 89-year-old patient with metastatic melanoma to the liver, lung and lymph nodes, who underwent treatment with Opdualag (combining anti-PD-1 nivolumab and anti-lymphocyte-activation gene 3 relatlimab ICBs), and developed pseudoprogression after two cycles of therapy. The patient experienced a radiographic increase in liver metastatic lesion size, but was found to have a subsequent reduction in these lesions. The patient has been on therapy for 18 months without evidence of disease progression and continues to be clinically well-appearing.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"133 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140631148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma. 基因表达谱分析对葡萄膜黑色素瘤患者转移后的诊断和存活率的影响。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-05 DOI: 10.1097/cmr.0000000000000971
D Suwajanakorn, A M Lane, A K Go, C D Hartley, M Oxenreiter, F Wu, E S Gragoudas, R J Sullivan, K Montazeri, I K Kim
Surveillance frequency for metastasis is guided by gene expression profiling (GEP). This study evaluated the effect of GEP on time to diagnosis of metastasis, subsequent treatment and survival. A retrospective study was conducted of 110 uveal melanoma patients with GEP (DecisionDx-UM, Castle Biosciences, Friendswood, Texas, USA) and 110 American Joint Committee on Cancer-matched controls. Surveillance testing and treatment for metastasis were compared between the two groups and by GEP class. Rates of metastasis, overall survival and melanoma-related mortality were calculated using Kaplan-Meier estimates. Baseline characteristics and follow-up time were balanced in the two groups. Patients' GEP classification was 1A in 41%, 1B in 25.5% and 2 in 33.6%. Metastasis was diagnosed in 26.4% (n = 29) in the GEP group and 23.6% (n = 26) in the no GEP group (P = 0.75). Median time to metastasis was 30.5 and 22.3 months in the GEP and no GEP groups, respectively (P = 0.44). Median months to metastasis were 34.7, 75.8 and 26.1 in class 1A, 1B and 2 patients, respectively (P = 0.28). Disease-specific 5-year survival rates were 89.4% [95% confidence interval (CI): 81.0-94.2%] and 84.1% (95% CI: 74.9-90.1%) in the GEP and no GEP groups respectively (P = 0.49). Median time to death from metastasis was 10.1 months in the GEP group and 8.5 months in the no GEP group (P = 0.40). There were no significant differences in time to metastasis diagnosis and survival outcomes in patients with and without GEP. To realize the full benefit of GEP, more sensitive techniques for detection of metastasis and adjuvant therapies are required.
基因表达谱(GEP)可指导转移瘤的监测频率。本研究评估了基因表达谱对转移瘤诊断时间、后续治疗和存活率的影响。研究人员对 110 名采用 GEP(DecisionDx-UM,Castle Biosciences,Friendswood,Texas,USA)的葡萄膜黑色素瘤患者和 110 名与美国癌症联合委员会匹配的对照组患者进行了回顾性研究。对两组患者的监测检测和转移治疗进行了比较,并按 GEP 分级进行了比较。转移率、总生存率和黑色素瘤相关死亡率采用卡普兰-梅耶估计法进行计算。两组患者的基线特征和随访时间均衡。41%患者的GEP分级为1A,25.5%为1B,33.6%为2。GEP组中有26.4%(n = 29)的患者确诊为转移,无GEP组中有23.6%(n = 26)的患者确诊为转移(P = 0.75)。GEP 组和无 GEP 组的中位转移时间分别为 30.5 个月和 22.3 个月(P = 0.44)。1A、1B和2级患者的中位转移月数分别为34.7、75.8和26.1个月(P = 0.28)。GEP组和无GEP组的疾病特异性5年生存率分别为89.4%[95%置信区间(CI):81.0-94.2%]和84.1%(95% CI:74.9-90.1%)(P = 0.49)。GEP组患者死于转移瘤的中位时间为10.1个月,无GEP组为8.5个月(P = 0.40)。有 GEP 和没有 GEP 的患者在转移瘤确诊时间和生存结果方面没有明显差异。要充分发挥GEP的疗效,还需要更灵敏的转移灶检测技术和辅助疗法。
{"title":"Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.","authors":"D Suwajanakorn, A M Lane, A K Go, C D Hartley, M Oxenreiter, F Wu, E S Gragoudas, R J Sullivan, K Montazeri, I K Kim","doi":"10.1097/cmr.0000000000000971","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000971","url":null,"abstract":"Surveillance frequency for metastasis is guided by gene expression profiling (GEP). This study evaluated the effect of GEP on time to diagnosis of metastasis, subsequent treatment and survival. A retrospective study was conducted of 110 uveal melanoma patients with GEP (DecisionDx-UM, Castle Biosciences, Friendswood, Texas, USA) and 110 American Joint Committee on Cancer-matched controls. Surveillance testing and treatment for metastasis were compared between the two groups and by GEP class. Rates of metastasis, overall survival and melanoma-related mortality were calculated using Kaplan-Meier estimates. Baseline characteristics and follow-up time were balanced in the two groups. Patients' GEP classification was 1A in 41%, 1B in 25.5% and 2 in 33.6%. Metastasis was diagnosed in 26.4% (n = 29) in the GEP group and 23.6% (n = 26) in the no GEP group (P = 0.75). Median time to metastasis was 30.5 and 22.3 months in the GEP and no GEP groups, respectively (P = 0.44). Median months to metastasis were 34.7, 75.8 and 26.1 in class 1A, 1B and 2 patients, respectively (P = 0.28). Disease-specific 5-year survival rates were 89.4% [95% confidence interval (CI): 81.0-94.2%] and 84.1% (95% CI: 74.9-90.1%) in the GEP and no GEP groups respectively (P = 0.49). Median time to death from metastasis was 10.1 months in the GEP group and 8.5 months in the no GEP group (P = 0.40). There were no significant differences in time to metastasis diagnosis and survival outcomes in patients with and without GEP. To realize the full benefit of GEP, more sensitive techniques for detection of metastasis and adjuvant therapies are required.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"80 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140601358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma. 达拉非尼和曲美替尼治疗转移性黑色素瘤引起的颅内出血。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-05 DOI: 10.1097/cmr.0000000000000820
Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin
Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.
虽然与化疗相比,转移性黑色素瘤的分子靶向治疗通常耐受性良好,但也可能出现危及生命的毒性反应。我们报告了一例接受达拉非尼加曲美替尼治疗的转移性黑色素瘤患者发生颅内出血的病例。医生应该了解这种罕见但危及生命的 B 型快速加速纤维肉瘤(BRAF)和丝裂原活化蛋白激酶激酶(MEK)不良事件。不过,他们应该注意出血的来源,这可能是黑色素瘤转移新发或抗凝剂过量,甚至是未得到控制的动脉高血压。
{"title":"Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.","authors":"Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin","doi":"10.1097/cmr.0000000000000820","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000820","url":null,"abstract":"Although generally well tolerated compared with chemotherapy, molecular targeted therapy used in metastatic melanoma may be associated with life-threatening toxicity. We report the case of a patient with metastatic melanoma treated by dabrafenib plus trametinib who developed intracranial hemorrhage. Physicians should be aware of this rare but life-threatening adverse event of B-rapidly accelerated fibrosarcoma (BRAF) and mitogen-activated protein kinase kinase (MEK). However, they should be careful about the bleeding origin, which can prove to be a new onset of melanoma metastasis or anticoagulation overdose, or even an uncontrolled arterial hypertension.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"30 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140601579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients. 一项对黑色素瘤患者进行的为期 10 年的回顾性研究显示,退变、退变程度和肿瘤浸润淋巴细胞对前哨节点状态、复发和存活率的影响。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-02 DOI: 10.1097/cmr.0000000000000970
Vincenzo Maione, Martina Perantoni, Luca Bettolini, Stefano Bighetti, Mariachiara Arisi, Cesare Tomasi, Paolo Incardona, Piergiacomo Calzavara-Pinton
This case-control study seeks to investigate the influence of histological findings, specifically regression, its extent and tumor-infiltrating lymphocyte (TILs), on result of sentinel lymph node (SLN) biopsy, 5-year melanoma-specific survival (MSS), and relapse-free survival (RFS). We included all patients with cutaneous melanoma who underwent SLN biopsy at the Melanoma Center of the University of Brescia, following the Italian Association of Medical Oncology National guidelines from January 2008 to August 2018. Regression and its extent (<75 or ≥75%) and the presence of TILs were reevaluated by a trained dermatopathologist, adhering to the 2017 College of American Pathologists Cancer Protocol for Skin Melanoma. These patients were followed up for 5 years. Our study uncovered significant associations between regression and male sex (P < 0.05), melanoma location on the trunk, upper limbs, and back (P = 0.001), ulceration (P < 0.05), lower Breslow thickness (P = 0.001), and the presence of lymphocytic infiltration (both brisk and nonbrisk) (P < 0.001). Regression and its extent, however, did not appear to affect SLN positivity (P = 0.315). Similarly, our data did not reveal a correlation between TILs and result of SLN biopsy (P = 0.256). When analyzing MSS and RFS in relation to the presence or absence of regression and TILs, no statistically significant differences were observed, thus precluding the need for logistic regression and Kaplan-Meier curve analysis. This study's findings underscore that regression and TILs do not appear to exert an influence on sentinel lymph node status,, MSS, or RFS in our cohort of patients.
这项病例对照研究旨在探讨组织学检查结果(尤其是退变、退变程度和肿瘤浸润淋巴细胞(TILs))对前哨淋巴结(SLN)活检结果、5年黑色素瘤特异性生存率(MSS)和无复发生存率(RFS)的影响。我们纳入了2008年1月至2018年8月期间在布雷西亚大学黑色素瘤中心接受前哨淋巴结活检的所有皮肤黑色素瘤患者,他们都遵循了意大利肿瘤内科学协会的国家指南。由训练有素的皮肤病理学家按照2017年美国病理学家学会皮肤黑色素瘤癌症协议对消退及其程度(<75或≥75%)和TIL的存在进行重新评估。对这些患者进行了为期 5 年的随访。我们的研究发现,回归与男性性别(P <0.05)、黑色素瘤位置在躯干、上肢和背部(P = 0.001)、溃疡(P <0.05)、较低的布瑞斯洛厚度(P = 0.001)以及存在淋巴细胞浸润(高危和非高危)(P <0.001)之间存在明显关联。然而,回归及其程度似乎并不影响 SLN 阳性率(P = 0.315)。同样,我们的数据也没有显示 TIL 与 SLN 活检结果之间存在相关性(P = 0.256)。在分析MSS和RFS与有无回归和TIL的关系时,没有观察到统计学上的显著差异,因此不需要进行逻辑回归和Kaplan-Meier曲线分析。本研究的结果强调,在我们的患者队列中,淋巴回缩和TIL似乎不会对前哨淋巴结状态、MSS或RFS产生影响。
{"title":"Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.","authors":"Vincenzo Maione, Martina Perantoni, Luca Bettolini, Stefano Bighetti, Mariachiara Arisi, Cesare Tomasi, Paolo Incardona, Piergiacomo Calzavara-Pinton","doi":"10.1097/cmr.0000000000000970","DOIUrl":"https://doi.org/10.1097/cmr.0000000000000970","url":null,"abstract":"This case-control study seeks to investigate the influence of histological findings, specifically regression, its extent and tumor-infiltrating lymphocyte (TILs), on result of sentinel lymph node (SLN) biopsy, 5-year melanoma-specific survival (MSS), and relapse-free survival (RFS). We included all patients with cutaneous melanoma who underwent SLN biopsy at the Melanoma Center of the University of Brescia, following the Italian Association of Medical Oncology National guidelines from January 2008 to August 2018. Regression and its extent (&lt;75 or ≥75%) and the presence of TILs were reevaluated by a trained dermatopathologist, adhering to the 2017 College of American Pathologists Cancer Protocol for Skin Melanoma. These patients were followed up for 5 years. Our study uncovered significant associations between regression and male sex (P &lt; 0.05), melanoma location on the trunk, upper limbs, and back (P = 0.001), ulceration (P &lt; 0.05), lower Breslow thickness (P = 0.001), and the presence of lymphocytic infiltration (both brisk and nonbrisk) (P &lt; 0.001). Regression and its extent, however, did not appear to affect SLN positivity (P = 0.315). Similarly, our data did not reveal a correlation between TILs and result of SLN biopsy (P = 0.256). When analyzing MSS and RFS in relation to the presence or absence of regression and TILs, no statistically significant differences were observed, thus precluding the need for logistic regression and Kaplan-Meier curve analysis. This study's findings underscore that regression and TILs do not appear to exert an influence on sentinel lymph node status,, MSS, or RFS in our cohort of patients.","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":"301 1","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140602229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simultaneous melanomas in the setting of multiple primary melanomas. 多发性原发性黑色素瘤中的同期黑色素瘤。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-01 Epub Date: 2024-01-15 DOI: 10.1097/CMR.0000000000000954
Maria Kostaki, Michaela Plaka, Aggeliki Befon, Clio Dessinioti, Katerina Kypraiou, Vasiliki Chardalia, Eleftheria Christofidou, Doris Polydorou, Alexandros Stratigos

It is estimated that about 1-13% of melanoma patients will develop multiple primary melanomas. Although the occurrence of subsequent tumors has been described during the last few years, the development of simultaneous melanomas has not yet been extensively studied. We reviewed our registries to identify patients with multiple primary melanomas. We studied epidemiological, clinical, and histological characteristics of patients who were diagnosed with simultaneous melanomas and compared them with those of patients who developed non-synchronous multiple primary melanomas. As simultaneous were defined subsequent melanomas that were diagnosed either at the same visit or within a time-period of maximum of 1 month. Between 2000 and 2020, 2500 patients were diagnosed with melanoma at Andreas Syggros Hospital. 86 (3.4%) patients presented multiple primary melanomas and among them, 35 (40.7%) developed simultaneous melanomas. Patients with simultaneous melanomas developed more frequently more than 2 tumors. First tumors of patients with non-synchronous melanomas were significantly thicker than second tumors while those of patients with simultaneous melanomas did not differ significantly. Slight differences in the tumor localization, staging and histologic type were observed between the two groups. However significant differences were ascertained between first and second tumors in both groups. Simultaneous melanomas occupy an important proportion of multiple primary melanomas, affecting a non-negligible number of patients. Slight differences between simultaneous and non-synchronous multiple primary melanomas seem to define a distinct subcategory of multiple primary melanomas.

据估计,约有 1-13% 的黑色素瘤患者会罹患多发性原发性黑色素瘤。虽然在过去几年中已经对后续肿瘤的发生进行了描述,但尚未对同时发生黑色素瘤的情况进行广泛研究。我们查阅了我们的登记资料,以确定有多个原发性黑色素瘤的患者。我们研究了确诊为同期黑色素瘤患者的流行病学、临床和组织学特征,并与非同期多发性原发性黑色素瘤患者的特征进行了比较。同时黑色素瘤是指在同一次就诊或最长 1 个月的时间内确诊的后续黑色素瘤。2000 年至 2020 年间,安德烈亚斯-西格罗斯医院共诊断出 2500 名黑色素瘤患者。86名患者(3.4%)患有多发性原发性黑色素瘤,其中35名患者(40.7%)同时患有黑色素瘤。同时罹患黑色素瘤的患者往往同时罹患两个以上的肿瘤。非同步黑色素瘤患者的第一个肿瘤明显比第二个肿瘤厚,而同步黑色素瘤患者的肿瘤则没有明显差异。两组患者的肿瘤定位、分期和组织学类型略有不同。不过,两组患者的第一和第二肿瘤之间存在明显差异。同时发生的黑色素瘤在多发性原发性黑色素瘤中占有重要比例,患者人数不可忽视。同时性和非同步性多发性原发性黑色素瘤之间的细微差别似乎定义了多发性原发性黑色素瘤的一个独特亚类。
{"title":"Simultaneous melanomas in the setting of multiple primary melanomas.","authors":"Maria Kostaki, Michaela Plaka, Aggeliki Befon, Clio Dessinioti, Katerina Kypraiou, Vasiliki Chardalia, Eleftheria Christofidou, Doris Polydorou, Alexandros Stratigos","doi":"10.1097/CMR.0000000000000954","DOIUrl":"10.1097/CMR.0000000000000954","url":null,"abstract":"<p><p>It is estimated that about 1-13% of melanoma patients will develop multiple primary melanomas. Although the occurrence of subsequent tumors has been described during the last few years, the development of simultaneous melanomas has not yet been extensively studied. We reviewed our registries to identify patients with multiple primary melanomas. We studied epidemiological, clinical, and histological characteristics of patients who were diagnosed with simultaneous melanomas and compared them with those of patients who developed non-synchronous multiple primary melanomas. As simultaneous were defined subsequent melanomas that were diagnosed either at the same visit or within a time-period of maximum of 1 month. Between 2000 and 2020, 2500 patients were diagnosed with melanoma at Andreas Syggros Hospital. 86 (3.4%) patients presented multiple primary melanomas and among them, 35 (40.7%) developed simultaneous melanomas. Patients with simultaneous melanomas developed more frequently more than 2 tumors. First tumors of patients with non-synchronous melanomas were significantly thicker than second tumors while those of patients with simultaneous melanomas did not differ significantly. Slight differences in the tumor localization, staging and histologic type were observed between the two groups. However significant differences were ascertained between first and second tumors in both groups. Simultaneous melanomas occupy an important proportion of multiple primary melanomas, affecting a non-negligible number of patients. Slight differences between simultaneous and non-synchronous multiple primary melanomas seem to define a distinct subcategory of multiple primary melanomas.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"198-201"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity. microRNA-9过表达对抑制黑色素瘤癌干细胞致瘤性的影响
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-01 Epub Date: 2024-01-15 DOI: 10.1097/CMR.0000000000000931
Sahranavardfard Parisa, Izadpanah Amirhossein, Yasavoli-Sharahi Hamed, Firouzi Javad, Azimi Masoumeh, Khosravani Pardis, Dorraj Mahshad, Keighobadi Faezeh, Ebrahimi Marzieh

Most of the studies have reported the downregulation of miR-9 in metastatic melanomas compared to primary tumors. They indicated that miR-9 negatively regulates the epithelial-to-mesenchymal transition (EMT) by inhibiting SNAIL1 expression and consequently promotes CDH1 expression. Since the process of EMT is associated to stem cell features, it could be interesting to study the effect of miR-9 on melanoma cancer stem cells. In the present study, we examined the effects of miR-9 manipulation on the stemness potential of melanoma cells. Our data demonstrated that the overexpression of miR-9 in A375 and NA8 cells significantly inhibits the ability of proliferation, self-renewal, migration, and tumorigenicity of melanoma cells which was concomitant with changes in the level of BRAF , some EMT factors, and stemness genes. Likewise, the reduction of miR-9 levels led to an increase in cell proliferation, colony and sphere formation, and the ability of cell migration and tumorigenicity. In conclusion, our results specified the role of miR-9 as a tumor suppressor miRNA to inhibit many aspects of melanoma stem cells, and therefore, it could be a potential candidate for the suppression of melanoma growth and progression.

与原发肿瘤相比,大多数研究都报道了转移性黑色素瘤中 miR-9 的下调。他们指出,miR-9通过抑制SNAIL1的表达负向调节上皮细胞向间质转化(EMT),从而促进CDH1的表达。由于 EMT 过程与干细胞特征有关,研究 miR-9 对黑色素瘤干细胞的影响可能很有意义。在本研究中,我们考察了操纵 miR-9 对黑色素瘤细胞干性潜能的影响。我们的数据表明,miR-9在A375和NA8细胞中的过表达会显著抑制黑色素瘤细胞的增殖、自我更新、迁移和致瘤性能力,并伴随着BRAF、一些EMT因子和干性基因水平的变化。同样,miR-9 水平的降低会导致细胞增殖、集落和球体形成、细胞迁移能力和致瘤性的增加。总之,我们的研究结果明确了miR-9作为肿瘤抑制miRNA对黑色素瘤干细胞多方面的抑制作用,因此,它可能是抑制黑色素瘤生长和进展的潜在候选者。
{"title":"The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.","authors":"Sahranavardfard Parisa, Izadpanah Amirhossein, Yasavoli-Sharahi Hamed, Firouzi Javad, Azimi Masoumeh, Khosravani Pardis, Dorraj Mahshad, Keighobadi Faezeh, Ebrahimi Marzieh","doi":"10.1097/CMR.0000000000000931","DOIUrl":"10.1097/CMR.0000000000000931","url":null,"abstract":"<p><p>Most of the studies have reported the downregulation of miR-9 in metastatic melanomas compared to primary tumors. They indicated that miR-9 negatively regulates the epithelial-to-mesenchymal transition (EMT) by inhibiting SNAIL1 expression and consequently promotes CDH1 expression. Since the process of EMT is associated to stem cell features, it could be interesting to study the effect of miR-9 on melanoma cancer stem cells. In the present study, we examined the effects of miR-9 manipulation on the stemness potential of melanoma cells. Our data demonstrated that the overexpression of miR-9 in A375 and NA8 cells significantly inhibits the ability of proliferation, self-renewal, migration, and tumorigenicity of melanoma cells which was concomitant with changes in the level of BRAF , some EMT factors, and stemness genes. Likewise, the reduction of miR-9 levels led to an increase in cell proliferation, colony and sphere formation, and the ability of cell migration and tumorigenicity. In conclusion, our results specified the role of miR-9 as a tumor suppressor miRNA to inhibit many aspects of melanoma stem cells, and therefore, it could be a potential candidate for the suppression of melanoma growth and progression.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"105-117"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma. 缺氧转录组预测皮肤黑色素瘤的存活率和肿瘤浸润免疫细胞的组成。
IF 2.2 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-04-01 Epub Date: 2024-02-07 DOI: 10.1097/CMR.0000000000000938
Michael J Diaz, Jessica Quach, Joanna Song, Silvija Milanovic, Jasmine T Tran, Lauren C Ladehoff, Sai Batchu, Patrick Whitman, Benajmin H Kaffenberger, Marjorie E Montanez-Wiscovich

Hypoxia has established associations with aggressive tumor phenotypes in many cancers. However, it is not currently understood whether tumor hypoxia levels map to distinct immune infiltrates in cutaneous melanoma, potentially unveiling novel therapeutic targets. To this end, we leveraged a previously identified seven-gene hypoxia signature to grade hypoxia levels of 460 cutaneous melanomas obtained from the Broad Institute GDAC Firehose portal. CIBERSORTx ( https://cibersortx.stanford.edu/ ) was employed to calculate the relative abundance of 22 mature human hematopoietic populations. Clinical outcomes and immune cell associations were assessed by computational means. Results indicated that patients with high-hypoxia tumors reported significantly worse overall survival and correlated with greater Breslow depth, validating the in-silico methodology. High-hypoxia tumors demonstrated increased infiltration of activated and resting dendritic cells, resting mast cells, neutrophils, and resting NK cells, but lower infiltration of gamma-delta T cells. These data suggest that high tumor hypoxia correlates with lower survival probability and distinct population differences of several tumor-infiltrating leukocytes in cutaneous melanomas.

缺氧与许多癌症的侵袭性肿瘤表型有关。然而,目前还不清楚肿瘤缺氧水平是否与皮肤黑色素瘤中不同的免疫浸润相关,从而可能揭示新的治疗靶点。为此,我们利用先前确定的七基因缺氧特征对从布罗德研究所 GDAC Firehose 门户网站获得的 460 例皮肤黑色素瘤的缺氧水平进行了分级。CIBERSORTx (https://cibersortx.stanford.edu/) 被用来计算 22 种成熟人类造血群体的相对丰度。通过计算手段评估了临床结果和免疫细胞关联。结果表明,高缺氧肿瘤患者的总生存率明显较低,且与布瑞斯洛深度相关,验证了室内方法学。高缺氧肿瘤显示活化和静止树突状细胞、静止肥大细胞、中性粒细胞和静止NK细胞浸润增加,但γ-δT细胞浸润较低。这些数据表明,肿瘤高缺氧与皮肤黑色素瘤较低的存活几率和几种肿瘤浸润白细胞明显的种群差异有关。
{"title":"Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.","authors":"Michael J Diaz, Jessica Quach, Joanna Song, Silvija Milanovic, Jasmine T Tran, Lauren C Ladehoff, Sai Batchu, Patrick Whitman, Benajmin H Kaffenberger, Marjorie E Montanez-Wiscovich","doi":"10.1097/CMR.0000000000000938","DOIUrl":"10.1097/CMR.0000000000000938","url":null,"abstract":"<p><p>Hypoxia has established associations with aggressive tumor phenotypes in many cancers. However, it is not currently understood whether tumor hypoxia levels map to distinct immune infiltrates in cutaneous melanoma, potentially unveiling novel therapeutic targets. To this end, we leveraged a previously identified seven-gene hypoxia signature to grade hypoxia levels of 460 cutaneous melanomas obtained from the Broad Institute GDAC Firehose portal. CIBERSORTx ( https://cibersortx.stanford.edu/ ) was employed to calculate the relative abundance of 22 mature human hematopoietic populations. Clinical outcomes and immune cell associations were assessed by computational means. Results indicated that patients with high-hypoxia tumors reported significantly worse overall survival and correlated with greater Breslow depth, validating the in-silico methodology. High-hypoxia tumors demonstrated increased infiltration of activated and resting dendritic cells, resting mast cells, neutrophils, and resting NK cells, but lower infiltration of gamma-delta T cells. These data suggest that high tumor hypoxia correlates with lower survival probability and distinct population differences of several tumor-infiltrating leukocytes in cutaneous melanomas.</p>","PeriodicalId":18550,"journal":{"name":"Melanoma Research","volume":" ","pages":"118-124"},"PeriodicalIF":2.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139702894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Melanoma Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1